Invivyd, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 30, 2026, reports significant corporate governance changes for Invivyd, Inc. (IVVD), a biotechnology company. The filing details the appointment of a new Chief Executive Officer and a new Board member, effective August 30, 2026.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive appointments and compensation arrangements.
Material Changes
- CEO Appointment: Marc Elia, previously Chairman of the Board, was appointed Chief Executive Officer (CEO), effective August 30, 2026. He succeeds William Duke, Jr., who remains Chief Financial Officer.
- Board Composition: The Board size increased from six to seven directors with the appointment of Ian Sheffield. Ajay Royan was appointed Lead Independent Director and replaced Mr. Elia as Chair of the Nominating and Corporate Governance Committee.
- Committee Assignments: Mr. Sheffield was appointed to the Compensation Committee and replaced Mr. Elia on the Audit Committee.
Compensation, Guidance, and Risks
Executive Compensation (Marc Elia):
- Base Salary: $750,000 annually.
- Target Bonus: 70% of base salary ($525,000), based on performance goals.
- Sign-On Bonus: One-time payment of $500,000.
- Equity Grant: Option to purchase 10,700,000 shares of common stock. The exercise price is the closing price on August 28, 2026. Vesting occurs over four years (25% on the first anniversary, then monthly).
- Change in Control Bonus: Eligible for a transaction bonus ranging from 0.5% to 1.5% of equity value for transactions valued at $5.0 billion or more.
- Severance: 12 months of base salary plus benefits for termination without cause; 18 months of base salary plus target bonus and full equity acceleration for termination without cause during a Change in Control period.
Director Compensation (Ian Sheffield):
- Cash Retainers: $40,000 annual board retainer, plus $7,500 for Audit Committee service and $5,000 for Compensation Committee service.
- Equity Grant: Option to purchase 100,000 shares of common stock, vesting over three years.
Outlook and Risks: The filing references a press release regarding the "DECLARATION" and "LIBERTY" studies for the company's asset VYD2311, indicating ongoing clinical development. No specific financial guidance or new risk factors were disclosed in this text.
Investor Verification Checklist
- Verify the closing stock price on August 28, 2026, to determine the exercise price for Marc Elia's 10.7 million share option grant.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Cause," "Good Reason," and performance metrics for the annual bonus.
- Confirm the status and results of the VYD2311 DECLARATION and LIBERTY studies referenced in the associated press release (Exhibit 99.1).
- Assess the impact of the 10.7 million share grant on existing shareholder dilution.